All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Abstract

Selegiline transdermal system in major depressive disorder

Author(s): Ashwin A Patkar, Kimberly B Portland,Chi-Un Pae

Selegiline transdermal system (STS) has been approved to treat major depressive disorder in the USA. STS represents a novel generation of monoamine oxidase inhibitors with a superior safety profile to older monoamine oxidase inhibitors, in particular with regard to food interactions. The efficacy and safety of STS has been established in shortand long-term clinical trials. STS expands the range of pharmacological treatment options available to clinicians to treat major depressive disorder, in particular major depressive disorder with atypical features or treatment-resistant depression. This article discusses the mechanism of action of STS, summarizes efficacy and safety data from clinical trials, reviews drug and food interactions with STS and offers suggestions for use of STS in clinical practice.


PDF

Share this       
Ledger Live desktop: Your secure gateway to crypto. Secure your assets with confidence using Ledger Live desktop. Experience a secure gateway that prioritizes the safety of your digital assets, providing peace of mind.